BioFactura Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 35

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $5.4M

  • Investors
  • 10

BioFactura General Information

Description

Developer of novel drugs designed to create biodefense vaccines and biological drugs against smallpox and Ebola. The company specializes in developing and manufacturing high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs using its patented StableFast Biomanufacturing Platform, enabling physicians to commercialize products to market with faster, lower cost at superior quality.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 8435 Progress Drive
  • Suite Z
  • Frederick, MD 21701
  • United States
+1 (301) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioFactura Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series C) 15-Mar-2022 $5.4M 000.00 00000 Completed Clinical Trials - Phase 1
10. Grant 01-Jan-2020 00000 00.000 Completed Clinical Trials - Phase 1
9. Later Stage VC (Series B) 29-Apr-2019 000 00.000 0000 Completed Clinical Trials - Phase 1
8. Grant 01-Jan-2018 00000 00.000 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A) 26-Apr-2016 00.000 00.000 00.00 Completed Clinical Trials - Phase 1
6. Grant 07-Apr-2016 0000 0000 Completed Clinical Trials - Phase 1
5. Accelerator/Incubator 04-Sep-2015 0000 Completed Clinical Trials - Phase 1
4. Grant 15-Sep-2014 0000 Completed Clinical Trials - Phase 1
3. Grant 26-Jun-2012 $1.88M $25K Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 31-Jan-2006 $25K $25K Completed Clinical Trials - Phase 1
To view BioFactura’s complete valuation and funding history, request access »

BioFactura Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 000
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view BioFactura’s complete cap table history, request access »

BioFactura Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel drugs designed to create biodefense vaccines and biological drugs against smallpox and Ebola. The com
Drug Discovery
Frederick, MD
35 As of 2024
000.00
00000 0000-00-00
00000000000 000.00

000000

ulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000 000000000
Cambridge, MA
0 As of 0000
00000
00000000 00000

000000

ctetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag
0000 000000000
Watertown, MA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioFactura Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synlogic Formerly VC-backed Cambridge, MA 0 00000 00000000 00000
EyePoint Pharmaceuticals Corporation Watertown, MA 000 00000 00000000 00000
Formycon Formerly VC-backed Martinsried, Germany 000 00000 000000000 00000
Xbrane Biopharma Formerly PE-Backed Solna, Sweden 00 00000 000000000 00000
Innovent Biologics Formerly PE-Backed Suzhou, China 0000 00.000 000000000 00.000
You’re viewing 5 of 50 competitors. Get the full list »

BioFactura Patents

BioFactura Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3289092-B1 Method of manufacturing a therapeutic protein Active 27-Apr-2015 000000000
EP-3289092-A1 Methods of manufacturing therapeutic proteins Active 27-Apr-2015 000000000
US-10774353-B2 Methods of manufacturing therapeutic proteins Active 27-Apr-2015 000000000 0
US-20180135090-A1 Methods of manufacturing therapeutic proteins Active 27-Apr-2015 000000000
ES-2789073-T3 Manufacturing method of a therapeutic protein Active 27-Apr-2015 C12P21/00
To view BioFactura’s complete patent history, request access »

BioFactura Executive Team (4)

Name Title Board Seat Contact Info
Darryl Sampey Ph.D Co-Founder, Chief Executive Officer, President and Board Member
Jeffrey Hausfeld MD Chief Medical Officer & Chairman
Alex DeSeabra Co-Founder & Board Member
You’re viewing 3 of 4 executive team members. Get the full list »

BioFactura Board Members (5)

Name Representing Role Since
Alex DeSeabra Self Co-Founder & Board Member 000 0000
Darryl Sampey Ph.D BioFactura Co-Founder, Chief Executive Officer, President and Board Member 000 0000
Dominic Eisinger Ph.D Self Board Member 000 0000
Jeffrey Hausfeld MD BioFactura Chief Medical Officer & Chairman 000 0000
You’re viewing 4 of 5 board members. Get the full list »

BioFactura Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioFactura Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
University Of Vermont Health Network Corporation Minority 000 0000 000000 0
Wilson Sonsini Goodrich & Rosati Corporation Minority 000 0000 000000 0
Jeffrey Hausfeld Angel (individual) Minority 000 0000 000000 0
Maryland Department of Commerce Government 000 0000 000000 0
St. Louis Development Lender/Debt Provider Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

BioFactura FAQs

  • When was BioFactura founded?

    BioFactura was founded in 2004.

  • Who is the founder of BioFactura?

    Darryl Sampey Ph.D, Alex Matschiner, and Alex DeSeabra are the founders of BioFactura.

  • Who is the CEO of BioFactura?

    Darryl Sampey Ph.D is the CEO of BioFactura.

  • Where is BioFactura headquartered?

    BioFactura is headquartered in Frederick, MD.

  • What is the size of BioFactura?

    BioFactura has 35 total employees.

  • What industry is BioFactura in?

    BioFactura’s primary industry is Drug Discovery.

  • Is BioFactura a private or public company?

    BioFactura is a Private company.

  • What is the current valuation of BioFactura?

    The current valuation of BioFactura is 00000.

  • What is BioFactura’s current revenue?

    The current revenue for BioFactura is 000000.

  • How much funding has BioFactura raised over time?

    BioFactura has raised $13.2M.

  • Who are BioFactura’s investors?

    University Of Vermont Health Network, Wilson Sonsini Goodrich & Rosati, Jeffrey Hausfeld, Maryland Department of Commerce, and St. Louis Development are 5 of 10 investors who have invested in BioFactura.

  • Who are BioFactura’s competitors?

    Synlogic, EyePoint Pharmaceuticals, Formycon, Xbrane Biopharma, and Innovent Biologics are some of the 50 competitors of BioFactura.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »